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We thank Lytras et al. [1] for the comments on our recent 
article assessing risk factors for mortality in inpatients 
with influenza and the effect of oseltamivir [2]. For this 
study, the authors are confident that the identification 
and adjustment for confounding variables have been 
done in a systematic and objective manner using step-
wise logistic regression. We note the concerns on the 
methods we have used, but we do not see how these 
concerns are specific to our work. Rather the concerns 
relate in general to the application of these methods.
We observed evidence of a protective association of 
full course 5 days treatment with oseltamivir against 
inpatient mortality, which emerged following adjust-
ment for the confounding variables we identified. We 
believe this is plausible, given that risk of death is 
widely recognised to be associated with comorbidities 
and age, and that oseltamivir is licensed as an effec-
tive medication for seasonal influenza with a rational 
drug design against a viral target.
It is the case that multiple testing using regression anal-
ysis has occurred and the authors agree that account-
ing for this could result in an upper limit exceeding 1. 
However, it would still be the case that evidence of an 
association between standard course of oseltamivir 
and protection against inpatient mortality was demon-
strated in a relatively large historic cohort of hospital-
ised patients receiving routine clinical care.
Lytras et al. [1] write that the final multivariable model 
contained nine predictors in a dataset with just 32 
outcome events (deaths), that our model was severely 
overfitted suggesting that the low prevalence of sev-
eral risk factors in the data hints at potential multicol-
linearity problems and that, both during the stepwise 
procedure and in the final model, Variance Inflation 
Factors for the covariates should have been included 
(i.e. in Table 2 of the article [2]). In response, we note 
there were only seven variables in the final model of 
Table 2 with a total of nine parameters and do not agree 
that there is universal acceptance of the 10 events per 
variable recommendation [3]. In any situation, the 
required number of observations could be more or less 
than this number. An over fitted model would be mani-
fested in extreme estimates and confidence intervals. 
All the estimates and confidence intervals presented 
are proportionate, with the wide confidence interval 
for ‘excessive alcohol use’ reflecting the few individu-
als with that factor. The nonlinear link function used 
in the logistic regression has meant that collinearity 
would have needed to have been severe for it to have 
caused difficulties, which would have been manifested 
in the estimates and confidence intervals.
With regard to delay in Table 3 of our study [2], for those 
not receiving oseltamivir, the delay was coded as zero. 
A binary variable defined to be one if antiviral given 
and zero otherwise was created in order to assess the 
impact of delay on mortality by interacting it with delay 
whenever delay was to be analysed.
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